Lv2
150 积分 2022-06-07 加入
An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies
14天前
已完结
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
15天前
已完结
Hope for patients with neuromyelitis optica spectrum disorders — from mechanisms to trials
22天前
已完结
Management of Spinal Muscular Atrophy in the Adult Population
1个月前
已完结
Safety Concerns with Nusinersen, Risdiplam, and Onasemnogene Abeparvovec in Spinal Muscular Atrophy: A Real-World Pharmacovigilance Study
1个月前
已完结
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial
3个月前
已完结
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial
3个月前
已完结
[Recommendations for the diagnosis and treatment of gout in China]
3个月前
已关闭
Gout: diagnosis and management—summary of NICE guidance
3个月前
已完结
Systematic literature review to inform the EULAR recommendations for the use of imaging in crystal-induced arthropathies in clinical practice
3个月前
已完结
皖公网安备34019202002308
